{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dube MP"],"funding":["British Heart Foundation","CIHR"],"pagination":["e003183"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8284376"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(2)"],"pubmed_abstract":["<h4>Background</h4>The randomized, placebo-controlled COLCOT (Colchicine Cardiovascular Outcomes Trial) has shown the benefits of colchicine 0.5 mg daily to lower the rate of ischemic cardiovascular events in patients with a recent myocardial infarction. Here, we conducted a post hoc pharmacogenomic study of COLCOT with the aim to identify genetic predictors of the efficacy and safety of treatment with colchicine.<h4>Methods</h4>There were 1522 participants of European ancestry from the COLCOT trial available for the pharmacogenomic study of COLCOT trial. The pharmacogenomic study's primary cardiovascular end point was defined as for the main trial, as time to first occurrence of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for"],"journal":["Circulation. Genomic and precision medicine"],"pubmed_title":["Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT."],"pmcid":["PMC8284376"],"funding_grant_id":["RE/18/6134217"],"pubmed_authors":["Lemieux Perreault LP","de Denus S","Fouodjio R","L'Allier PL","Lemacon A","Mongrain I","Sun M","Kouz S","Cossette M","Blondeau L","Guertin MC","Dubois A","Tardif JC","Lopez-Sendon J","Gamra H","Pinto FJ","Roubille F","Asselin G","Koenig W","Kiwan GS","Bouabdallaoui N","Berry C","Dube MP","Barhdadi A","Maggioni AP","Diaz R","Rhainds D","Provost S","Samuel M","Legault MA","Waters DD"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT.","description":"<h4>Background</h4>The randomized, placebo-controlled COLCOT (Colchicine Cardiovascular Outcomes Trial) has shown the benefits of colchicine 0.5 mg daily to lower the rate of ischemic cardiovascular events in patients with a recent myocardial infarction. Here, we conducted a post hoc pharmacogenomic study of COLCOT with the aim to identify genetic predictors of the efficacy and safety of treatment with colchicine.<h4>Methods</h4>There were 1522 participants of European ancestry from the COLCOT trial available for the pharmacogenomic study of COLCOT trial. The pharmacogenomic study's primary cardiovascular end point was defined as for the main trial, as time to first occurrence of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-04T21:11:09.148Z","creation":"2022-02-11T02:24:20.573Z"},"accession":"S-EPMC8284376","cross_references":{"pubmed":["33560138"],"doi":["10.1161/CIRCGEN.120.003183"]}}